Givaudan SA
DUS:GIN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Givaudan SA
DUS:GIN
|
CH |
|
G
|
Glencore PLC
OTC:GLCNF
|
CH |
|
C
|
Close Brothers Group PLC
OTC:CBGPF
|
UK |
|
P
|
ProMIS Neurosciences Inc
F:23J0
|
CA |
|
Manulife Financial Corp
TSX:MFC
|
CA |
|
N
|
NetEase Inc
SWB:NEH
|
CN |
|
I
|
IDEXX Laboratories Inc
SWB:IX1
|
US |
|
U
|
United Parcel Service Inc
SWB:UPAB
|
US |
|
N
|
Novo Nordisk A/S
XBER:NOVA
|
DK |
|
Soditech SA
PAR:SEC
|
FR |
Wall St Price Targets
GIN Price Targets Summary
Givaudan SA
According to Wall Street analysts, the average 1-year price target for GIN is 3 757.44 EUR with a low forecast of 2 873.79 EUR and a high forecast of 5 170.85 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is GIN's stock price target?
Price Target
3 757.44
EUR
According to Wall Street analysts, the average 1-year price target for GIN is 3 757.44 EUR with a low forecast of 2 873.79 EUR and a high forecast of 5 170.85 EUR.
What is the Revenue forecast for Givaudan SA?
Projected CAGR
4%
Over the last 14 years, the compound annual growth rate for Revenue has been 5%. The projected CAGR for the next 7 years is 4%.
What is the Operating Income forecast for Givaudan SA?
Projected CAGR
4%
Over the last 14 years, the compound annual growth rate for Operating Income has been 8%. The projected CAGR for the next 7 years is 4%.
What is the Net Income forecast for Givaudan SA?
Projected CAGR
6%
Over the last 14 years, the compound annual growth rate for Net Income has been 11%. The projected CAGR for the next 5 years is 6%.
